Citations

Mayo Clinic

Showing 10 of 108522 citations.

LONG-TERM RESULTS OF THE BIRMINGHAM HIP RESURFACING IMPLANT IN THE UNITED STATES: AN UPDATED ANALYSIS OF A SINGLE INSTITUTION'S EXPERIENCE
Zuke, William A. , Kromka, Joseph , Clohisy, John C. , Barrack, Robert L. , Hannon, Charles P. , Granger, C.

Orthopaedic Proceedings | August 19, 2024 | Volume: 106-B | Issue: SUPP_16 | Pages: 39-39

10.1302/1358-992x.2024.16.039 Get It

We previously reported the five to ten-year results of the Birmingham Hip Resurfacing (BHR) implant. The purpose of this study was to evaluate the survivorship, radiographic results, and clinical outcomes of the BHR at long-term follow-up.We retrospectively reviewed 250 patients from the original cohort of 324 BHRs performed from 2006 to 2013 who met contemporary BHR indications. Of these, 4 patients died and 4 withdrew. From the 242 patients, 224 patients (93%) were available for analysis. Modified Harris hip score (mHHS) and University of California, Los Angeles (UCLA) scores were collected and compared to a matched total hip arthroplasty (THA) cohort. Mean follow-up was 14 years.Survivorship free of aseptic revision was 97.4% and survivorship free of any revision was 96.0% at 15 years. Revisions included 3 periprosthetic joint infections, 2 for elevated metal ions and symptomatic pseudotumor, 2 for aseptic femoral loosening, and 1 for unexplained pain. The mean mHHS was 93 in BHR patients at final follow-up, similar to the THA cohort (p=0.44). The UCLA score was significantly higher for BHR patients (p=0.02), however there were equal proportions of patients who remained highly active (UCLA 9 or 10) in both groups, 60.5% and 52.2% (p=0.45) for BHR and THA respectively. Metal ion levels at long term follow-up were low (mean serum cobalt 1.8±1.5 ppb and mean serum chromium 2.2±2.0 ppb).BHR demonstrated excellent survivorship in males less than 60 years of age at time of surgery. Clinical outcomes and activity levels were similar to THA patients. Failures related to the metal-on-metal bearing were rare and metal levels were low at long-term follow-up.Level of evidence: IIIKeywords: survivorship; hip arthroplasty; activity; metal-on-metalSurface Replacement Arthroplasty demonstrates low revision rates and similar activity level compared to total hip arthroplasty at long-term follow-up.
TOTAL HIP ARTHROPLASTY IN PATIENTS WITH ANGULAR PROXIMAL FEMORAL DEFORMITIES
Dagneaux, Louis , Lewallen, David G. , Trousdale, R T, Abdel, Matthew P. , Sierra, Rafael J. , Berry, Daniel J.

Orthopaedic Proceedings | August 19, 2024 | Volume: 106-B | Issue: SUPP_16 | Pages: 24-24

10.1302/1358-992x.2024.16.024 Get It

Angular proximal femoral deformities increase the technical complexity of primary total hip arthroplasties (THAs). The goals were to determine the long-term implant survivorship, risk factors, complications, and clinical outcomes of contemporary primary THAs in this difficult cohort.Our institutional total joint registry was used to identify 119 primary THAs performed in 109 patients with an angular proximal femoral deformity between 1997 and 2017. The deformity was related to previous femoral osteotomy in 85%, and developmental or metabolic disorders in 15%. 53% had a predominantly varus angular deformity. The mean age was 44 years, mean BMI was 29 kg/m2, and 59% were female. An uncemented metaphyseal fixation stem was used in 30%, an uncemented diaphyseal fixation stem in 28%, an uncemented modular body stem with metaphyseal fixation sleeve in 24%, and a cemented stem in 18%. Simultaneous corrective femoral osteotomy was performed in 18%. Kaplan-Meier survivorships and Harris hip scores were reported. Mean follow-up was 8 years.The 10-year survivorships free of femoral loosening, aseptic femoral revision, any revision, and any reoperation were 95%, 93%, 90% and 88%, respectively. Revisions occurred in 13 hips for: aseptic femoral component loosening (3), stem fracture (2), dislocation (2), aseptic acetabular loosening (2), polyethylene liner exchange (2), and infection (2). Preoperative varus angular deformities were associated with a higher risk of any revision (HR 10, p=0.03), and simultaneous osteotomies with a higher risk of any reoperation (HR 3.6, p=0.02). Mean Harris hip scores improved from 52 preoperatively to 82 at 10 years (p<0.001).In the largest series to date of primary THAs in patients with angular proximal femoral deformities, we found a good 10-year survivorship free from any revision. Varus angular deformities, particularly those treated with a simultaneous osteotomy due to the magnitude or location of the deformity, had a higher reoperation rate.Keywords: Proximal femoral deformity; dysplasia; femoral osteotomy; survivorship; revisionLevel of evidence: Level III, comparative retrospective cohort
Massive fetomaternal hemorrhage from placental abruption presenting as weak‐D expression
Durowoju, Lindsey, Hasan, Rida A. , Hess, John R. , Sabath, Daniel E. , Bryan, Andrew , Pagano, Monica B. , Tsang, Hamilton C. , Pagano, Monica B , Tsang, Hamilton C , Bryan, Andrew , Hasan, Rida A

Transfusion | August 19, 2024 | Volume: 64 | Issue: 10 | Pages: 1820-1821

10.1111/trf.17988 | PMID 39157966 Get It

Loss of HD-PTP function results in lipodystrophy, defective cellular signaling and altered lipid homeostasis
Schultz, Destiny F. , Davies, Brian A., Payne, Johanna A., Martin, Cole P , Minard, Annabel Y. , Childs, Bennett G. , Jeganathan, Karthik B. , Sturmlechner, Ines , White, Thomas A. , Harkema, Liesbeth , Chen, Huiqin , Davies, Michael A. , Jachim, Sarah K. , Hu, Li , Deursen, Jan M. van , Billadeau, Daniel D. , Katzmann, David J. , Jeganathan, Karthik B , Sturmlechner, Ines , de Bruin, Alain , Harkema, Liesbeth , Jachim, Sarah , LeBrasseur, Nathan K , Piper, Robert C , Baker, Darren J , van Deursen, Jan M , Billadeau, Daniel D , Katzmann, David J , Zhang, Cheng , Bruin, Alain de , LeBrasseur, Nathan K. , Piper, Robert C. , Baker, Darren J.

Journal of Cell Science | August 19, 2024 | Volume: 137 | Issue: 18 | Pages: No page available

10.1242/jcs.262032 | PMID 39155850 Get It

ABSTRACT His domain protein tyrosine phosphatase (HD-PTP; also known as PTPN23) facilitates function of the endosomal sorting complexes required for transport (ESCRTs) during multivesicular body (MVB) formation. To uncover its role in physiological homeostasis, embryonic lethality caused by a complete lack of HD-PTP was bypassed through generation of hypomorphic mice expressing reduced protein, resulting in animals that are viable into adulthood. These mice exhibited marked lipodystrophy and decreased receptor-mediated signaling within white adipose tissue (WAT), involving multiple prominent pathways including RAS/MAPK, phosphoinositide 3-kinase (PI3K)/AKT and receptor tyrosine kinases (RTKs), such as EGFR. EGFR signaling was dissected in vitro to assess the nature of defective signaling, revealing decreased trans-autophosphorylation and downstream effector activation, despite normal EGF binding. This corresponds to decreased plasma membrane cholesterol and increased lysosomal cholesterol, likely resulting from defective endosomal maturation necessary for cholesterol trafficking and homeostasis. The ESCRT components Vps4 and Hrs have previously been implicated in cholesterol homeostasis; thus, these findings expand knowledge on which ESCRT subunits are involved in cholesterol homeostasis and highlight a non-canonical role for HD-PTP in signal regulation and adipose tissue homeostasis.
The effect of radiation or chemotherapy on the local recurrence, overall survival, and distant metastasis in patients with myxofibrosarcoma: A systematic review
Tibbo, Meagan E. , Landau, Rebecca , Markowitz, Moses I. , Abuodeh, Yousef , Temple, H. Thomas , Crawford, Brooke , Abuodeh, Yousef

Journal of Surgical Oncology | August 19, 2024 | Volume: 130 | Issue: 3 | Pages: 586-593

10.1002/jso.27782 | PMID 39155707 Get It

AbstractBackground and ObjectivesManagement of myxofibrosarcoma (MFS) is widely debated, and there is no consensus regarding the effect of adjuvant therapies on local recurrence (LR), distant metastasis (DM), or overall survival (OS). This study aims to determine the effect of adjuvant therapies on the aforementioned outcomes in patients with MFS.MethodsWe conducted a systematic review via Medline, PubMed, CINAHL, Cochrane, Embase, and Google Scholar. Therapeutic studies that reported LR, DM, and OS following adjuvant therapies in patients with MFS were included. Statistical analysis and creation of hazard ratios were performed using Revman 5.3 (Cochrane Collaboration).ResultsWe identified 301 studies, 10 of which were included in the final analysis. Neither chemotherapy nor radiation affected the rate of LR (p = 0.73 and 0.17, respectively) or OS (p = 0.97 and 0.27, respectively). Chemotherapy was significantly associated with lower rates of DM (p = 0.03); however, there was no association between radiation and DM (p = 0.67).ConclusionThere is a lack of consensus regarding the effect of neoadjuvant and adjuvant therapies on LR, DM, and OS in patients with MFS. Our systematic review found that radiation and chemotherapy were not significantly associated with OS or LR in patients with MFS. However, we identified a significant association between chemotherapy and lower rates of DM.
The Effect of Increased Intra-Abdominal Pressure on Hemodynamics in Laparoscopic Cholecystectomy—The Experience of a Single Centre
Stamate, Elena , Piraianu, Alin Ionut , Duca, Oana-Monica , Ciobotaru, Oana Roxana , Fulga, Ana , Onișor, Cristian , Matei, Madălina Nicoleta , Luchian, Alexandru-Stefan, Dumitrascu, Adrian , Ciobotaru, Octavian Cătălin , Onisor, Cristian , Dumitrascu, Adrian George , Ciobotaru, Octavian Catalin , Ciobotaru, Oana Roxana , Fulga, Iuliu

Journal of Personalized Medicine | August 19, 2024 | Volume: 14 | Issue: 8 | Pages: 871

10.3390/jpm14080871 | PMID 39202062 Get It

Laparoscopic cholecystectomy is characterized by reduced postoperative pain, shorter hospital stays, rapid return to preoperative physical activity, and less psychological impact on the patient. During laparoscopic cholecystectomy, the intra-abdominal insufflation of carbon dioxide with secondary increase in intra-abdominal pressure can cause important hemodynamic consequences, like decreased cardiac output and blood pressure, as well as compensatory increase in heart rate. The purpose of this study is to evaluate changes in cardiovascular parameters during general anesthesia in patients undergoing laparoscopic cholecystectomy. Retrospective data from 342 patients with cholecystectomy for cholelithiasis performed at Railway Hospital Galati, Romania, were reviewed. All patients received the same intraoperative anesthetics. Female patients were 85.7% (n = 293). More than half of the patients, 53.51% (n = 183), were 40–59 years old, and only 16.37% (n = 56) were under 40 years old. Patients with a normal body mass index (BMI) represented 45.6% (n = 156), 33.3% (n = 114) were underweight, and 12% (n = 42) had grade 1 obesity (BMI 25–29.9 kg/m2). The minimum intraoperative blood pressure correlated with patient gender (p 0.015 < 0.005), with men having a higher blood pressure than women (p 0.006 < 0.05), and for BMI, a higher BMI was associated with elevated blood pressure (p 0.025 < 0.05). Older age correlated with an increased maximum intraoperative blood pressure (p < 0.001 < 0.05) and with maximum intraoperative heart rate (p 0.015 < 0.05). Patients undergoing laparoscopic cholecystectomy experienced significant hemodynamic changes with pneumoperitoneum, but this type of surgical intervention was safe for patients regardless of their age.
Defining the Spatial Resolution of Analyte Recovery during Microperfusion-Based Sampling of Brain Parenchyma
Stangler, Luke A, Chang, Su-Youne , Kim, Inyong , Bennet, Kevin E. , Howe, Charles L. , Choi, Jonghoon, Howe, Charles L , Choi, Jonghoon , Kouzani, Abbas Z. , Burns, Terry C. , Gompel, Jamie J. Van , Worrell, Gregory A.

ACS Chemical Neuroscience | August 19, 2024 | Volume: 15 | Issue: 17 | Pages: 3220-3227

10.1021/acschemneuro.4c00410 | PMID 39155540 Get It

Treatment for chronic idiopathic constipation: Use and satisfaction from a nationwide survey of US participants
Lacy, Brian E. , Xu, Yanqing , Taylor, Douglas C.A., Kosch, Katherine J., Dobrescu, Rachel, Morlock, Amy, Morlock, Robert , Rooker, Ceciel, Rooker, Ceciel

Neurogastroenterology & Motility | August 19, 2024 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/nmo.14885 | PMID 39155456 Get It

AbstractBackgroundChronic idiopathic constipation (CIC) is a disorder of gut–brain interaction characterized by a variety of bowel movement‐related and abdominal symptoms. A greater understanding of medication use and satisfaction with symptom control may provide insights to optimize patient care. Therefore, we explored these aspects of the disorder in adults with CIC.MethodsThis study assessed data collected from a large nationwide survey of adult participants in the United States, querying demographics, clinical characteristics, and comorbid conditions, as well as medication use, care‐seeking behaviors, and satisfaction with symptom control. Participants were grouped into the CIC cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self‐reported.Key ResultsTwo thousand five hundred and thirty‐three participants with CIC were matched 1:1 to controls. In the CIC cohort, abdominal pain was the most reported symptom leading to medication use: 15.9% of respondents were receiving a prescription medication in addition to an over‐the‐counter medication, while 26.3% were taking neither. In addition, only one‐third were satisfied with the control of their symptoms; however, satisfaction was significantly higher in respondents taking a prescription medication (p < 0.001). The proportion of reported comorbidities was significantly higher in the CIC cohort versus the control cohort, with chronic pain, anxiety, and depression among the highest (p < 0.001 for all).Conclusions and InferencesThis study emphasizes the need for better communication regarding prescription medications and their benefits, with the goal of further improving CIC patients' overall symptoms.
Representation of women in clinical trials supporting FDA ‐approval of contemporary cancer therapies
Kalathoor, Sujay , Ghazi, Sanam , Otieno, Beryl, Babcook, Melissa A., Chen, Sunnia T. , Nidhi, Neha, Bae, Junu, Pierre‐Charles, Jovan , Breathett, Khadijah , Mazimba, Sula , Mohammed, Selma F. , Carter, Rebecca R. , Ferdousi, Mussammat , Kola‐Kehinde, Onaopepo , McLaughlin, Eric , Brammer, Jonathan E. , Ruz, Patrick, Khan, Sarah , Odei, Bismarck , Patel, Prem, Addison, Daniel , Breathett, Khadijah , Nidhi, Neha, Johnson, Amber E , Brewer, LaPrincess C. , Bonsu, Janice M. , Mitchell, Darrion , Wei, Lai , Patel, Prem, Paskett, Electra D.

International Journal of Cancer | August 19, 2024 | Volume: 155 | Issue: 11 | Pages: 1958-1968

10.1002/ijc.35110 | PMID 39155749 Get It

Abstract Contemporary anticancer therapies frequently have different efficacy and side effects in men and women. Yet, whether women are well‐represented in pivotal trials supporting contemporary anticancer drugs is unknown. Leveraging the Drugs@FDA database, clinicaltrials.gov , MEDLINE, and publicly available FDA‐drug‐reviews, we identified all pivotal (phase II and III) non‐sex specific trials supporting FDA‐approval of anticancer drugs (1998–2018). Observed‐enrollment‐rates were compared to expected‐population‐rates derived from concurrent US‐National‐Cancer‐Institute's Surveillance‐Epidemiology‐and‐End‐Results (SEER) reported rates and US‐Census databases. Primary outcome was the proportional representation of women across trials, evaluated by a participation‐to‐prevalence ratio (PPR), according to cancer type. Secondary outcome was the report of any sex‐specific analysis of efficacy and/or safety, irrespective of treatment‐arm. Overall, there were 148 trials, enrolling 60,216 participants (60.5 ± 4.0 years, 40.7% female, 79.1% biologic, targeted, or immune‐based therapies) evaluating 99 drugs. Sex was reported in 146 (98.6%) trials, wherein 40.7% (24,538) were women, compared to 59.3% (35,678) men ( p < .01). Altogether, women were under‐represented in 66.9% trials compared to the proportional incidence of cancers by respective disease type; weight‐average PPR of 0.91 (relative difference: ‐9.1%, p < .01). Women were most under‐represented in gastric (PPR = 0.63), liver (PPR = 0.71), and lung (PPR = .81) cancer trials. Sex‐based safety data was reported in 4.0% trials. There was no association between adequate female enrollment and drug efficacy (HR: 0.616 vs. 0.613, p = .96). Over time, there was no difference in the percentage of women recruited into clinical trials. Among pivotal clinical trials supporting contemporary FDA‐approved cancer drugs, women were frequently under‐represented and sex‐specific‐efficacy and safety‐outcomes were commonly not reported.
Clinical Management of Endometriosis in Menopause: A Narrative Review
Dave, D. , Page, Heidi E., Carrubba, Aakriti R. , Dave, Dhruva

Medicina | August 19, 2024 | Volume: 60 | Issue: 8 | Pages: 1341

10.3390/medicina60081341 | PMID 39202622 Get It

Endometriosis, an inflammatory disease primarily affecting the pelvis and peritoneum, manifests with pelvic pain, dysmenorrhea, dyschezia, dyspareunia, and infertility. Despite its ubiquity, the management of endometriosis is challenging due to its heterogeneous presentation, limitations in diagnostic methods, variable therapeutic responses, and personal and socio-cultural impact on quality of life. This review attempts to consolidate the current literature on endometriosis occurring during and beyond menopause, and to present details regarding management strategies that take into account individual outcomes and goals when managing this condition. The topics included in this review are the clinical features and differential diagnosis of pelvic pain in postmenopausal patients, imaging considerations, serum and laboratory biomarkers, indications for surgery, the principles of hormone replacement therapy, the de novo development of endometriosis after menopause, and malignant transformation. Each topic includes a summary of the current literature, utilizing clinical research, case reports, and expert opinion. Despite a better understanding of the impact of endometriosis beyond menopause, there are many limitations to this condition, specifically with regard to cancer risk and indications for surgery. The existing evidence supports the use of shared decision making and the incorporation of patient preferences in guiding clinical management. Future research endeavors must shed light on the natural history of postmenopausal endometriosis through longitudinal studies in order to foster a deeper understanding of its complicated disease course across women’s lifespans.